CFLCA: High Performance based Heart disease Prediction System using Fuzzy Learning with Neural Networks

Human Diseases are increasing rapidly in today’s generation mainly due to the life style of people like poor diet, lack of exercises, drugs and alcohol consumption etc. But the most spreading disease that is commonly around 80% of people death direct and indirectly heart disease basis. In future (approximately after 10 years) maximum number of people may expire cause of heart diseases. Due to these reasons, many of researchers providing enormous remedy, data analysis in various proposed technologies for diagnosing heart diseases with plenty of medical data which is related to heart disease. In field of Medicine regularly receives very wide range of medical data in the form of text, image, audio, video, signal pockets, etc. This database contains raw dataset which consist of inconsistent and redundant data. The health care system is no doubt very rich in aspect of storing data but at the same time very poor in fetching knowledge. Data mining (DM) methods can help in extracting a valuable knowledge by applying DM terminologies like clustering, regression, segmentation, classification etc. After the collection of data when the dataset becomes larger and more complex than data mining algorithms and clustering algorithms (D-Tree, Neural Networks, K-means, etc.) are used. To get accuracy and precision values improved with proposed method of Cognitive Fuzzy Learning based Clustering Algorithm (CFLCA) method. CFLCA methodology creates advanced meta indexing for n-dimensional unstructured data. The heart disease dataset used after data enrichment and feature engineering with UCI machine learning algorithm, attain high level accurate and prediction rate. Through this proposed CFLCA algorithm is having high accuracy, precision and recall values of data analysis for heart diseases detection

Sepsis: Epidemiology, Pathophysiology, Classification, Biomarkers and Management

Every physician has been trained early in their careers on how to recognize and manage sepsis. Although sepsis has been one of the most researched ailments in medicine, it also remains one of the deadliest diseases in the face of recent advances. In this current article, we review the diagnostic and management criteria for Systemic Inflammatory Response Syndrome (SIRS), sepsis, severe sepsis, septic shock, and Multi Organ Dysfunction Syndrome (MODS). We then examine the implications of the “surviving sepsis” campaign as well as explore the philosophy of Early Goal Directed Therapy (EGDT) and its role in the modern day management of sepsis. In addition, we sought to highlight potential new biomarkers and current available therapies in sepsis

Overcoming challenges in organofluorine biosynthesis by engineered fluorinases

Please click Additional Files below to see the full abstract

Overcoming challenges in organofluorine biosynthesis by engineered fluorinases

Please click Additional Files below to see the full abstract

In-depth behavioral study of l-Prolinium Trichloroacetate single crystal: An efficient candidate for NLO applications

AbstractOrganic compounds have constantly proved to be a proficient candidate for nonlinear optical (NLO) applications. In this respect an organic amino acid compound i.e. l-Prolinium Trichloroacetate single crystal has been synthesized and grown through slow evaporation solution growth technique. The lattice parameters obtained from single crystal X-ray diffraction were comparable with reported one. The diffraction pattern along the strain present inside the crystal was measured through powder X-ray diffraction technique. Its photoconductivity has also been observed, in which the traits of dark and photon current were recorded over a range of applied voltage. Further, birefringence was performed for the sample in which it was found that the crystal is having negative optical homogeneity character. The thermal transport parameters were calculated through photo-pyroelectric technique. Its resistance toward the laser beam was examined using laser damage threshold technique. The mechanical characteristics of the single crystal were determined on nanoscale using Oliver–Pharr method

QM/MM Studies of The phenylalanine ammonia-lyase variants helped to understand the mechanistic role of the mutations

Please click Additional Files below to see the full abstract

Vedolizumab for induction and maintenance of remission in Crohn's disease

Vedolizumab blocks inflammatory activity within the gastrointestinal tract. Systematic reviews have demonstrated the efficacy of vedolizumab in ulcerative colitis and inflammatory bowel disease in general. This systematic review and meta-analysis summarises the current evidence of vedolizumab in the induction and maintenance of remission in Crohn's disease. To evaluate the benefits and harms of vedolizumab versus placebo for the induction and maintenance of remission in people with Crohn's disease. We used standard, extensive Cochrane search methods. The latest search date was 30 November 2022. We included randomised controlled trials (RCTs) and quasi-RCTs comparing vedolizumab to placebo for the induction or maintenance of remission in people with Crohn's disease. We used standard Cochrane methods. For induction studies, the primary outcome was 1. clinical remission, and secondary outcomes were rates of 2. clinical response, 3. adverse events, 4. serious adverse events, 5. surgery, 6. endoscopic remission and 7. endoscopic response. For maintenance studies, the primary outcome was 1. maintenance of clinical remission, and secondary outcomes were rates of 2. adverse events, 3. serious adverse events, 4. surgery, 5. endoscopic remission and 6. endoscopic response. We used GRADE to assess certainty of evidence. We analysed induction (4 trials, 1126 participants) and maintenance (3 trials, 894 participants) studies representing people across North America, Europe, Asia and Australasia separately. One maintenance trial administered subcutaneous vedolizumab whilst the other studies used the intravenous form. The mean age ranged between 32.6 and 38.6 years. Vedolizumab was superior to placebo for the induction of clinical remission (71 more per 1000 with clinical remission with vedolizumab; risk ratio (RR) 1.61, 95% confidence interval (CI) 1.20 to 2.17; number needed to treat for an additional beneficial outcome (NNTB) 13; 4 studies; high-certainty evidence) and superior to placebo for inducing clinical response (105 more per 1000 with clinical response with vedolizumab; RR 1.43, 95% CI 1.19 to 1.71; NNTB 8; 4 studies; high-certainty evidence). For the induction phase, vedolizumab may be equivalent to placebo for the development of serious adverse events (9 fewer serious adverse events per 1000 with vedolizumab; RR 0.91, 95% CI 0.62 to 1.33; 4 studies; low-certainty evidence) and probably equivalent to placebo for overall adverse events (6 fewer adverse events per 1000 with vedolizumab; RR 1.01, 95% CI 0.93 to 1.11; 4 studies; moderate-certainty evidence). Vedolizumab was superior to placebo for the maintenance of clinical remission (141 more per 1000 with maintenance of clinical remission with vedolizumab; RR 1.52, 95% CI 1.24 to 1.87; NNTB 7; 3 studies; high-certainty evidence). During the maintenance phase, vedolizumab may be equivalent to placebo for the development of serious adverse events (3 fewer serious adverse events per 1000 with vedolizumab; RR 0.98, 95% CI 0.68 to 1.39; 3 studies; low-certainty evidence) and probably equivalent to placebo for the development of overall adverse events (0 difference in adverse events per 1000; RR 1.00, 95% CI 0.94 to 1.07; 3 studies; moderate-certainty evidence). High-certainty data across four induction and three maintenance trials demonstrate that vedolizumab is superior to placebo in the induction and maintenance of remission in Crohn's disease. Overall adverse events are probably similar and serious adverse events may be similar between vedolizumab and placebo during both induction and maintenance phases of treatment. Head-to-head research comparing the efficacy and safety of vedolizumab to other biological therapies is required. [Abstract copyright: Copyright © 2023 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.

Enhancement of thermoelectric figure of merit in Bi2Se3 crystals through a necking process

The growth of good quality bulk single crystals of bismuth selenide by employing a high-temperature vertical Bridgman technique with a specially designed ampoule having a provision for a necking process is reported. Several growth experiments were performed and reproducible results were obtained. The crystal structure and lattice dimensions were confirmed by powder X-ray diffraction (PXRD), the bulk crystalline perfection was assessed using high-resolution X-ray diffractometry and the good bulk crystalline perfection with an indication of layered structure was confirmed. Transmission electron microscopy (TEM) was carried out for the grown single crystal and confirmed the layered structure. High-resolution TEM (HRTEM) was also used to further assess the crystalline perfection. The direct measurement of d spacing obtained from HRTEM imaging was found to be in good agreement with the data obtained from PXRD. The thermal behavior was examined by differential scanning calorimetry and a sharp melting was found at 983K, which revealed the purity of the bismuth selenide. The Seebeck coefficient and electrical and thermal conductivities were measured, and a thermoelectric figure of merit was calculated in order to assess the suitability of the crystal for thermoelectric applications such as refrigeration and portable power generation. Nanoindentation analysis was also performed for the first time

Genomic data analysis workflows for tumors from patient-derived xenografts (PDXs): challenges and guidelines.

BACKGROUND: Patient-derived xenograft (PDX) models are in vivo models of human cancer that have been used for translational cancer research and therapy selection for individual patients. The Jackson Laboratory (JAX) PDX resource comprises 455 models originating from 34 different primary sites (as of 05/08/2019). The models undergo rigorous quality control and are genomically characterized to identify somatic mutations, copy number alterations, and transcriptional profiles. Bioinformatics workflows for analyzing genomic data obtained from human tumors engrafted in a mouse host (i.e., Patient-Derived Xenografts; PDXs) must address challenges such as discriminating between mouse and human sequence reads and accurately identifying somatic mutations and copy number alterations when paired non-tumor DNA from the patient is not available for comparison. RESULTS: We report here data analysis workflows and guidelines that address these challenges and achieve reliable identification of somatic mutations, copy number alterations, and transcriptomic profiles of tumors from PDX models that lack genomic data from paired non-tumor tissue for comparison. Our workflows incorporate commonly used software and public databases but are tailored to address the specific challenges of PDX genomics data analysis through parameter tuning and customized data filters and result in improved accuracy for the detection of somatic alterations in PDX models. We also report a gene expression-based classifier that can identify EBV-transformed tumors. We validated our analytical approaches using data simulations and demonstrated the overall concordance of the genomic properties of xenograft tumors with data from primary human tumors in The Cancer Genome Atlas (TCGA). CONCLUSIONS: The analysis workflows that we have developed to accurately predict somatic profiles of tumors from PDX models that lack normal tissue for comparison enable the identification of the key oncogenic genomic and expression signatures to support model selection and/or biomarker development in therapeutic studies. A reference implementation of our analysis recommendations is available at https://github.com/TheJacksonLaboratory/PDX-Analysis-Workflows